Payers can face challenges in using appropriate management strategies close to launch. It’s difficult to have a complete picture of a therapy or device when manufacturers hesitate sharing certain information amid unclear FDA regulations. (more…)
Traditional FDA approval is based on large clinical trial populations and Phase III data, but that approach may not work for a variety of newer targeted drugs, including gene therapies. (more…)
We are excited to announce that Precision Value & Health has been ranked #6 in MM&M magazine’s Agency Top 100 list! With a 10.6% increase in revenue from the previous year, we are continuing to add talent and services–partnering with pharmaceutical and life sciences companies to ensure patient access to life-changing therapies.
EXPANDED EMPHASIS ON INTERPRETING THE SCIENCE OF COMPLEX MEDICAL INNOVATIONS
BOLSTERS PRECISION’S CAPABILITIES TO SUPPORT COMMERCIAL AND R&D CLIENT BASE
Bethesda, MD – Tuesday, July 10, 2018 – Precision Medicine Group, LLC., announced it is acquiring ETHOS Health Communications, a Pennsylvania-based agency specializing in the interpretation and communication of innovative medical science. The acquisition of ETHOS, which informs physicians, providers and other stakeholders through medical affairs- and marketing-based scientific content, allows Precision to offer its clients a significantly expanded cadre of doctoral-level science and medical communications specialists.
As more gene and CAR-T therapies enter the market, especially in therapeutic categories with more patients such as cancer, experts say manufacturers will have to up their game in establishing the true value of their therapies, and work closely with payers on payment agreements. Precision for Value experts Jeremy Schafer and Alex Grosvenor offer their perspectives in this MedAd News cover story.
(more…)
To bring gene therapies to market sooner the FDA plans to speed up approvals by evaluating these therapies’ impact on “surrogate end points.” (more…)
Precision for Value’s Joseph Honcz shares top takeaways from the recent Anthem-Aspire acquisition, and the continued effort by managed care entities to enter the business of senior care management.
At the ASCO Annual Meeting in Chicago, PHE Senior Director, Policy & Economics Julia Thornton-Snider, PhD presented a recently-completed study on the impact of treatment delays for patients with pediatric leukemia. (more…)
In this article Larry Blandford, EVP and managing partner at Precision Xtract, offers initial impressions of the Trump Administration’s blueprint to lower drug prices – American Patients First. (more…)
Precision is pleased to announce that Dan Renick has been named as one of PM360 Magazine’s annual ELITE Award winners. Congratulations, Dan! (more…)